iShares US Pharmaceuticals ETF
86 hedge funds and large institutions have $259M invested in iShares US Pharmaceuticals ETF in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 25 increasing their positions, 34 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less capital invested
Capital invested by funds: $259M → $259M (-$439K)
1% less funds holding
Funds holding: 87 → 86 (-1)
4.24% less ownership
Funds ownership: 109.58% → 105.34% (-4.2%)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
26% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$3.59M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.34M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.24M |
| 4 |
AWA
ARS Wealth Advisors
St. Petersburg,
Florida
|
+$1.5M |
| 5 |
ACM
Avalon Capital Management
Port Of Redwood City,
California
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWM
Braver Wealth Management
Needham,
Massachusetts
|
-$6.49M |
| 2 |
SAM
Stringer Asset Management
Memphis,
Tennessee
|
-$4.55M |
| 3 |
U
UBS
Zurich,
Switzerland
|
-$3.31M |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$3.08M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$2.73M |
IHE Hedge Fund Activity: Q3 2014 in Review
86 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2014, worth a combined $259M — down 0.17% from $259M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IHE and 6 opened new positions — a net loss of 1 holder — while 34 trimmed existing stakes and 25 added.
The largest buyer was Bank of America, adding an estimated $3.59M. The largest seller was Braver Wealth Management, exiting entirely with an estimated $6.49M sold.
- 86 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2014, down from 87 in Q2 2014.
- Funds reported $259M of iShares US Pharmaceuticals ETF stock for Q3 2014, down 0.17% quarter-over-quarter.
- 6 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2014 and 7 closed out, a net change of -1 holder.
- The largest iShares US Pharmaceuticals ETF buyer in Q3 2014 was Bank of America, an estimated $3.59M added.
- The largest iShares US Pharmaceuticals ETF seller in Q3 2014 was Braver Wealth Management, an estimated $6.49M sold.
Based on aggregated 13F filings for Q3 2014.